Why Contraceptive Innovation?

Despite the availability of various contraceptive methods, more than 200 million women in developing countries want to avoid or delay pregnancy yet are not using an effective family planning method. For some of these women, access to contraception is limited. For others, currently available methods do not meet their needs or preferences or are unaffordable. Innovative solutions are needed in the areas of product development, registration, pricing, and introduction to address these barriers.

Join the exchange and become part of the solution!

Visit our resource library for additional information about the need for contraceptive innovation.


A one-stop shop for resources related to contraceptive research and development

The CTI Exchange offers resources about contraceptive research and development, including information about products currently in development, preclinical and clinical research, and opportunities for future investment. This easily searchable resource library also includes information about regulatory requirements, quality assurance standards, intellectual property, and product introduction strategies, as well as tools for advocacy.

View all resources


Latest news, events, resources, and thought pieces from the Exchange's blog


Getting Behind Human-Centered Design for Contraceptive Innovation
With high unmet need for family planning methods still present, a huge opportunity exists to look at new ways to design products that respond to women’s needs and preferences, rather than ...

Vaginal Rings: The Future is Now
Successes and lessons learned from Progering and Dapivrine —the first vaginal rings to be introduced—will be critical in informing the introduction of the rings currently in development.

Blocking Sperm by Reinforcing Cervical Mucus
How novel would it be if one of women’s own natural barriers – cervical mucus – could be the basis for a highly effective, game-changing contraceptive.

Sperm Motility Inhibited in Study of Male Macaques
Newly published research suggests that EP055 could become the basis for an effective, reversible, short-acting, non-hormonal male contraceptive.

Building the Foundation for Developing Next-Gen Contraceptives
Discovery of new contraceptive agents will remain elusive unless something changes to dramatically improve the state-of-the-art for contraceptive screening and pre-clinical testing, making t...

A Chicken or Egg Dilemma: Reducing Commodity Costs When Scaling u...
In the past decade, use of contraceptive implants in sub-Saharan Africa has increased dramatically, in large part due to major reductions in price. 

IMPT Seminar to Focus on Longer-Acting Technologies
“Opportunities and Challenges for Long-Acting MPTs,” the second in a series of technical webinars focused on multi-purpose technologies, will be held on May 2.

Why Women-Centered MPT Development Matters
Social, behavioral, and gender influences that shape women’s and girls’ ability to use MPT products are key both early, in product design, and later, in product introduction efforts.

High-Tech Fertility Awareness: Moving Beyond the Beads
Fertility apps designed to prevent or plan pregnancy are attractive to women because they are free of side effects, help them understand their fertility, and can be accessed entirely through...

Introducing Sayana Press into Senegal Method Mix
Introducing Sayana Press in Senegal meant encouraging the population to accept the product, ensuring its availability within health facilities, and promoting its effective distribution by he...

A Fresh Start to Female Condom Marketing
The introduction of the Woman's Condom, coupled with targeted marketing and education, will lead to increased interest in trying female condom products and more protected sex.

Daré Bioscience & Orbis Biosciences to Collaborate on Injectable...
Daré Bioscience and Orbis Biosciences will collaborate on development of two etonogestrel-based, longer-acting injectable contraceptives.

Featured Resources

Other key resources related to contraceptive research and development

Calliope, the Contraceptive Pipeline Database, includes information on potential contraceptive targets and leads, products in development, and a selection of products only available in limited markets.
CAPRI, the Contraceptive Active Pharmaceutical Ingredient Database, lists biological and chemical properties for 27 active pharmaceutical ingredients found in contraceptives, along with data on their pharmacology, toxicology, impurities, metabolites, and use in marketed products.


We want you to join the exchange!

The CTI Exchange looks to partners to help generate and share resources. Contact us with your ideas, materials, or questions, or sign up to receive more information. We also encourage you to provide your feedback